MRNA
Moderna Inc.
$24.54
+$0.21(+0.86%)
40
Overall
60
Value
10
Tech
50
Quality
Market Cap
$9.24B
Volume
10.38M
52W Range
$23.04 - $48.92
Target Price
$39.05
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $135.1M | $60.2M | $803.0M | $18.5B | $19.3B | $6.8B | $3.2B | ||
| Total Revenue | $135.1M | $60.2M | $274.0M | $17.7B | $18.9B | $6.8B | $3.2B | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | $8.0M | $2.6B | $5.4B | $4.7B | $1.5B | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $135.1M | $60.2M | $266.0M | $15.1B | $13.5B | $2.2B | $1.8B | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $548.3M | $605.9M | $1.6B | $2.6B | $4.0B | $6.4B | $5.7B | ||
| Research & Development | $454.1M | $496.3M | $1.4B | $2.0B | $3.3B | $4.8B | $4.5B | ||
| Research Expense | $454.1M | $496.3M | $1.4B | $2.0B | $3.3B | $4.8B | $4.5B | ||
| Selling, General & Administrative | $94.3M | $109.6M | $188.0M | $567.0M | $1.1B | $1.5B | $1.2B | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | $121.0M | $204.0M | $146.0M | ||
| General & Administrative Expenses | $94.3M | $109.6M | $188.0M | $567.0M | $1.1B | $1.5B | $1.2B | ||
| Depreciation & Amortization | $24.9M | $31.0M | $31.0M | $232.0M | $348.0M | $617.0M | $185.0M | ||
| Depreciation & Amortization | $24.9M | $31.0M | $31.0M | -- | -- | -- | -- | ||
| Amortization | -- | $309.0K | $1.0M | $189.0M | $280.0M | $552.0M | $74.0M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-413.3M | $-545.7M | $-763.0M | $13.3B | $9.4B | $-4.2B | $-3.9B | ||
| EBITDA | $-359.5M | $-477.2M | $-703.1M | $13.5B | $9.9B | $-3.3B | $-3.4B | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | $6.6M | $9.9M | $18.0M | -- | -- | -- | ||
| Intinc | $27.0M | $38.5M | $25.0M | $18.0M | $200.0M | $421.0M | $425.0M | ||
| Net Non-Operating Interest Income/Expense | $27.0M | $38.5M | $25.0M | $18.0M | $-171.0M | $421.0M | $425.0M | ||
| Other Income/Expense | $-1.8M | $7.5M | $6.0M | $29.0M | $-16.0M | $124.0M | $87.0M | ||
| Other Special Charges | $1.8M | $-7.5M | $-6.0M | $-29.0M | $-45.0M | $-124.0M | $-87.0M | ||
| SPECIAL ITEMS | |||||||||
| Special Income Charges | -- | -- | $-1.6M | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | $1.6M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-384.4M | $-508.2M | $-734.1M | $13.3B | $9.6B | $-3.9B | $-3.6B | ||
| Pre-Tax Income | $-384.4M | $-514.7M | $-744.0M | $13.3B | $9.6B | $-3.9B | $-3.6B | ||
| INCOME TAX | |||||||||
| Tax Provision | $326.0K | $-695.0K | $3.0M | $1.1B | $1.2B | $772.0M | $-46.0M | ||
| NET INCOME | |||||||||
| Net Income | $-384.7M | $-514.0M | $-747.0M | $12.2B | $8.4B | $-4.7B | $-3.6B | ||
| Net Income (Continuing Operations) | $-384.7M | $-514.0M | $-747.0M | $12.2B | $8.4B | $-4.7B | $-3.6B | ||
| Net Income (Discontinued Operations) | $-384.7M | $-514.0M | $-747.0M | $12.2B | $8.4B | $-4.7B | $-3.6B | ||
| Net Income (Common Stockholders) | $-401.9M | $-514.0M | $-747.0M | $12.2B | $8.4B | $-4.7B | $-3.6B | ||
| Normalized Income | -- | -- | -- | -- | -- | $-3.1B | $-3.7B | ||
| TOTALS | |||||||||
| Total Expenses | $548.3M | $605.9M | $1.6B | $5.2B | $9.5B | $11.1B | $7.2B | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $81.1M | $330.8M | $381.3M | $403.0M | $394.0M | $382.0M | $384.0M | ||
| Average Shares Outstanding (Diluted) | $81.1M | $330.8M | -- | $431.0M | $416.0M | $382.0M | $384.0M | ||
| Shares Outstanding | $329.0M | $368.6M | $399.8M | $402.9M | $386.3M | $382.1M | $385.8M | ||
| Basic EPS | $-4.95 | $-1.55 | $-1.96 | $30.31 | $21.26 | $-12.33 | $-9.28 | ||
| Basic EPS (Continuing Operations) | $-4.95 | $-1.55 | $-1.96 | $30.31 | $21.26 | $-12.33 | $-9.28 | ||
| Diluted EPS | $-4.95 | $-1.55 | $-1.96 | $28.29 | $20.12 | $-12.33 | $-9.28 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $28.29 | $20.12 | $-12.33 | $-9.28 | ||
| OTHER METRICS | |||||||||
| Accretion On Preferred Stock | $4.1M | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | $13.0M | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $94.3M | $109.6M | $188.0M | $567.0M | $1.1B | $1.5B | $1.2B | ||
| Otherunder Preferred Stock Dividend | $17.1M | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $17.1M | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $19.1M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MRNA | $24.54 | +0.9% | 10.38M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |